• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA Approves Drug for New Use in Treatment of Psoriatic Arthritis

Article

Washington--The Food and Drug Administration has approved Humira, a drug used to treat rheumatoid arthritis (RA), for additional use in the treatment of psoriatic arthritis, which is associated with psoriasis.

Washington--The Food and Drug Administration has approved Humira, a drug used to treat rheumatoid arthritis (RA), for additional use in the treatment of psoriatic arthritis, which is associated with psoriasis.

Humira blocks a protein called tumor necrosis factor alpha, or TNF-alpha, which is released by the immune system and causes joint swelling and other damage.

The FDA based its approval of the new use of Humira on a clinical trial involving 313 psoriatic arthritis patients who did not respond after being treated with anti- non-steroidal anti-inflammatory drugs.

The FDA also approved Humira for initial use in patients with moderate to severe (RA). Previously, it was approved for use only after other drug treatments failed.

Related Videos
Video 2 - "Atopic Dermatitis and Contact Dermatitis: Navigating Intersecting Pathways and Optimal Management Strategies"
Video 1 - "Decoding Atypical Atopic Dermatitis: Unraveling Complex Cases and Advanced Diagnostic Strategies"
Elizabeth Kiracofe, MD, an expert on atopic dermatitis
© 2024 MJH Life Sciences

All rights reserved.